SCHEMBL2052285

SCHEMBL2052285

O=[N+]([O-])C=Cc1ccc(O)c(O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 1.00
ABL1 P00519 2/20 1.00
ABL2 P42684 2/20 1.00
VCP P55072 3/20 0.66
ALDH1A1 P00352 2/20 0.66
LMNA P02545 2/20 0.66
MAPT P10636 2/20 0.66
MAPK1 P28482 2/20 0.66
GALR2 O43603 1/20 0.66
HTT P42858 1/20 0.66
SYK P43405 1/20 0.66
SMN1; SMN2 Q16637 1/20 0.66
NPSR1 Q6W5P4 1/20 0.66
FBP1 P09467 9/20 0.63
LCK P06239 2/20 0.59
XDH P47989 1/20 0.53
NQO2 P16083 1/20 0.52
KDM4E B2RXH2 2/20 0.52
HSD17B10 Q99714 2/20 0.52
MEN1 O00255 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2052283 1.00 EGFR (1.00) EGFRABL1ABL2VCPALDH1A1
SCHEMBL29371330 1.00 EGFR (1.00) EGFRABL1ABL2VCPALDH1A1
SCHEMBL3667077 0.96 EGFR (0.93) EGFRABL1ABL2VCPALDH1A1
SCHEMBL3667079 0.96 EGFR (0.93) EGFRABL1ABL2VCPALDH1A1
SCHEMBL13773077 0.84 EGFR (0.72) EGFRABL1ABL2VCPALDH1A1
SCHEMBL8010226 0.84 EGFR (0.72) EGFRABL1ABL2VCPALDH1A1
SCHEMBL11239202 0.84 EGFR (0.72) EGFRABL1ABL2VCPALDH1A1
SCHEMBL2027151 0.84 EGFR (0.72) EGFRABL1ABL2VCPALDH1A1
SCHEMBL2027152 0.84 EGFR (0.72) EGFRABL1ABL2VCPALDH1A1
SCHEMBL8012584 0.84 EGFR (0.72) EGFRABL1ABL2VCPALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108794337-A A kind of new preparation process of 3,4- dihydroxy-beta-nitrostyrene 上海华堇生物技术有限责任公司 2018-11-13 CN claimed
JP-4425628-B2 2010-03-03 JP claimed
EP-1435894-A4 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO PHARMACEUTICALS INC (US) 2005-07-06 EP claimed
JP-2005505519-A 2005-02-24 JP claimed
EP-1435894-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS Galileo Pharmaceuticals, Inc. (US) 2004-07-14 EP claimed
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2003-04-17 US claimed
WO-2003009807-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO LABORATORIES, INC. (US) 2003-02-06 WO claimed
US-20250326747-A1 Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2 AUSPEX PHARMACEUTICALS LLC 2025-10-23 US disclosed
US-11505549-B2 Process for preparation of Deutetrabenazine ALAPARTHI, Lakshmi Prasad (IN) 2022-11-22 US disclosed
US-20220267317-A1 Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2 AUSPEX PHARMACEUTICALS INC (US) 2022-08-25 US disclosed
US-11421223-B2 Processes and host cells for genome, pathway, and biomolecular engineering ENEVOLV, INC. (US) 2022-08-23 US disclosed
CN-112961093-A Method for reducing C = C double bond of nitroolefin with high selectivity 北京化工大学 2021-06-15 CN disclosed
US-20210047317-A1 A NOVEL PROCESS FOR PREPARATION OF DEUTETRABENAZINE ALAPARTHI, Lakshmi Prasad (IN) 2021-02-18 US disclosed
US-20050113416-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods GALILEO PHARMACEUTICALS, INC. 2005-05-26 US disclosed
EP-1435894-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS Galileo Pharmaceuticals, Inc. (US) 2004-07-14 EP disclosed
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2003-04-17 US disclosed
WO-2003009807-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO LABORATORIES, INC. (US) 2003-02-06 WO disclosed
US-6162614-A Sugar ester derivatives, reagents for measurement of hydrolase activity and methods for measurement of hydrolase activity TOYO BOSEKI KABUSHIKI KAISHA (JP) 2000-12-19 US disclosed
EP-0346912-B1 Sugar ester derivatives, reagents for measurement of hydrolase activity and methods for measurement of hydrolase activity TOYO BOSEKI (JP) 1997-12-17 EP disclosed
US-4153696-A RENAL CIRCULATION PROMOTERS DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) 1979-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220267317-A1 Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2 SLC18A2, SLC6A2, SLC18A1 EGFR 4787/4885ABL1 478/4885ABL2 1504/4885
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 EGFR 3617/4885ABL1 4324/4885ABL2 4428/4885
US-20250326747-A1 Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2 SLC18A2, SLC6A2, SLC18A1 EGFR 4787/4885ABL1 478/4885ABL2 1504/4885
US-11505549-B2 Process for preparation of Deutetrabenazine CYP4X1, DRD4, CHRM5 EGFR 3309/4885ABL1 2741/4885ABL2 3222/4885
US-20050113416-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 EGFR 3617/4885ABL1 4324/4885ABL2 4428/4885
US-20210047317-A1 A NOVEL PROCESS FOR PREPARATION OF DEUTETRABENAZINE DRD4, DDO, CYP4X1 EGFR 3652/4885ABL1 3097/4885ABL2 3490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.